MAP Kinase Signaling
p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb |
イイネ！(4) | 
|
| CSTコード | 包装 | 希望納入価格 (円) |
国内在庫  2012年2月8日17時20分 現在 |
|
|---|---|---|---|---|
| #4695S | 200 μL | 46,000 | ログインすると国内在庫状況がご確認いただけます。
| |
| #4695P | 40 μL for Custom Sampler Kit |  Custom Antibody Sampler Kitの構成品を選択できます。 5本以上を選択し、ページ右上のCartから製品確定書を発行してください。 尚、構成品の単品販売は致しておりません。 |
シグナル伝達研究応援キャンペーン プレゼント *Pサイズのみ
|
4695 の推奨プロトコール 最適な結果を得るために：Cell Signaling Technology (CST) 社は、各製品の推奨プロトコールを使用することを強くお薦めいたします。 注：各製品に最適化されたプロトコールをリンクしています。 |
|---|
下記ステップについては、データシートの右側もあわせてご参照ください。
IHC-P: 抗体希釈液 / 抗原賦活化
| 用途 (希釈倍率) | |
|---|---|
| ウェスタンブロッティング (1:1,000)、免疫沈降 (1:50)、免疫組織染色 (パラフィン) (1:250)、免疫蛍光細胞染色 (IF-IC) (1:100)、フローサイトメトリー (1:100) |
| 種交差性 | |
|---|---|
| ヒト、マウス、ラット、サル、ミンク、ブタ、ハムスター、ウシ、キイロショウジョウバエ、ゼブラフィッシュ、イヌ、線虫、(ニワトリ) |
| 特異性・感度 | |
|---|---|
| 内在性レベルのp44/42 MAPK (Erk1/2) タンパク質を検出します。JNK/SAPK あるいはp38 MAPK とは交差しません。 |
| 検出タンパク質の分子量 | |
|---|---|
| 42 kDa、44 kDa |
| 使用抗原 | |
|---|---|
| ラットのp44 MAPK タンパク質のC末端近傍領域 (合成ペプチド) |
| 抗体の由来 | |
|---|---|
| ウサギ |
| 貯法 | |
|---|---|
| -20℃ |
| ※括弧付きの動物種は、配列が100%相同であるため反応すると推定されます。 |
| 社内データ |
|---|
Western Blotting
Western blot analysis of extracts from HeLa, NIH/3T3 and C6 cells, using p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb.
Western Blotting
Western blot analysis of extracts from Hek 293 cells, transfected with 100 nM SignalSilence® Control siRNA (Fluorescein Conjugate) #6201 (-) or SignalSilence® p44/42 MAPK (Erk1/2) siRNA (+), using p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb #4695 and α-Tubulin (11H10) Rabbit mAb #2125. The p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb confirms silencing of p44/42 expression and α-Tubulin (11H10) Rabbit mAb is used to control for loading and specificity of p44/42 MAPK (Erk1/2) siRNA.
IHC-P (paraffin)
Immunohistochemical analysis of paraffin-embedded human breast carcinoma, showing cytoplasmic and nuclear localization, using p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb.
IHC-P (paraffin)
Immunohistochemical analysis of paraffin-embedded human colon carcinoma, using p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb.
IHC-P (paraffin)
Immunohistochemical analysis of paraffin-embedded human breast carcinoma, using p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb in the presence of control peptide (left) or #1240 p44/42 MAPK (Erk1/2) Blocking Peptide (#4695 Specific) (right).
Flow Cytometry
Flow cytometric analysis of Jurkat cells, U0126-treated (blue) or PMA-treated (green), using p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb compared to a nonspecific negative control antibody (red).
IF-IC
Confocal immunofluorescent analysis of NIH/3T3 cells, treated with either U0126 (MEK1/2 Inhibitor) #9903 (left) or PDGF (right), using p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb (green). Actin filaments have been labeled with DY-554 phalloidin (red).
IF-IC
Confocal immunofluorescent analysis of HT-1080 cells, serum-starved (left) or treated with phorbol di-butyrate (PDBu) (100 nM for 15 min) (right) using p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb (green). Actin filaments were labeled with DY-554 phalloidin (red).
| バックグラウンド |
|---|
Mitogen-activated protein kinases (MAPKs) are a widely conserved family of serine/threonine protein kinases involved in many cellular programs such as cell proliferation, differentiation, motility, and death. The p44/42 MAPK (Erk1/2) signaling pathway can be activated in response to a diverse range of extracellular stimuli including mitogens, growth factors, and cytokines (1-3) and is an important target in the diagnosis and treatment of cancer (4). Upon stimulation, a sequential three-part protein kinase cascade is initiated, consisting of a MAP kinase kinase kinase (MAPKKK or MAP3K), a MAP kinase kinase (MAPKK or MAP2K), and a MAP kinase (MAPK). Multiple p44/42 MAP3Ks have been identified, including members of the Raf family as well as Mos and Tpl2/Cot. MEK1 and MEK2 are the primary MAPKKs in this pathway (5,6). MEK1 and MEK2 activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187, respectively. Several downstream targets of p44/42 have been identified, including p90RSK (7) and the transcription factor Elk-1 (8,9). p44/42 are negatively regulated by a family of dual-specificity (Thr/Tyr) MAPK phosphatases, known as DUSPs or MKPs (10), along with MEK inhibitors such as U0126 and PD98059.
- Roux, P.P. and Blenis, J. (2004) Microbiol Mol Biol Rev 68, 320-44.
- Baccarini, M. (2005) FEBS Lett 579, 3271-7.
- Meloche, S. and Pouysségur, J. (2007) Oncogene 26, 3227-39.
- Roberts, P.J. and Der, C.J. (2007) Oncogene 26, 3291-310.
- Rubinfeld, H. and Seger, R. (2005) Mol Biotechnol 31, 151-74.
- Murphy, L.O. and Blenis, J. (2006) Trends Biochem Sci 31, 268-75.
- Dalby, K.N. et al. (1998) J Biol Chem 273, 1496-505.
- Marais, R. et al. (1993) Cell 73, 381-93.
- Kortenjann, M. et al. (1994) Mol Cell Biol 14, 4815-24.
- Owens, D.M. and Keyse, S.M. (2007) Oncogene 26, 3203-13.
| 使用文献 |
|---|
- Yang, P. et al. (2010) Nat Immunol 11, 487-94. Applications: Western Blotting
- Kang, L. et al. (2010) Mol Endocrinol 24, 709-21. Applications: Western Blotting
- Rohani, M.G. et al. (2010) BMC Immunol 11, 53. Applications: Western Blotting
- Miyaji, M. et al. (2009) Proc Natl Acad Sci U S A 106, 14502-7. Applications: Western Blotting
- Dumesic, P.A. et al. (2009) J Cell Biol 185, 409-22. Applications: IHC-P (paraffin) Western Blotting
- Mabilleau, G. and Sabokbar, A. (2009) PLoS ONE 4, e4173. Applications: Western Blotting
- Gray, M.J. et al. (2008) J Natl Cancer Inst 100, 109-20. Applications: Western Blotting
- Rygiel, T.P. et al. (2008) J Cell Sci 121, 1183-92. Applications: Western Blotting
- Engelman, J.A. et al. (2008) Nat Med 14, 1351-6. Applications: Western Blotting
- Hyman, J.M. et al. (2009) Proc Natl Acad Sci U S A 106, 14132-7. Applications: Western Blotting
本製品は試験研究用です。